Research output

Research output per year 2008 2015 2020 2021 2022 2023 2024

• 63 Article
• 28 Review article
• 6 Chapter
• 3 Editorial
• 4 More
  • 2 Comment/debate
  • 2 Short survey

Research output per year

Research output per year

Search results

• 2024

  Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting

  Saberzadeh-Ardestani, B., Jones, J. C., McWilliams, R. R., Tougeron, D., Halfdanarson, T. R., Guimbaud, R., Hubbard, J. M., Fleccia, C., Shi, Q., Alouani, E., Sonbol, M. B., Ticku, J., Jin, Z., Taieb, J. & Sinicrope, F. A., Jan 2024, In: European Journal of Cancer. 196, 113433.

  Research output: Contribution to journal › Article › peer-review

  • Colorectal Neoplasms 66%
  • Progression-Free Survival 43%
  • Neoplasm Metastasis 37%
  • Liver 30%
  • Neoplasms 15%

• Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

  Emiloju, O. E., Yin, J., Koubek, E., Reid, J. M., Borad, M. J., Lou, Y., Seetharam, M., Edelman, M. J., Sausville, E. A., Jiang, Y., Kaseb, A. O., Posey, J. A., Davis, S. L., Gores, G. J., Roberts, L. R., Takebe, N., Schwartz, G. K., Hendrickson, A. E. W., Kaufmann, S. H., Adjei, A. A., & 2 othersHubbard, J. M. & Costello, B. A., Feb 2024, In: Investigational New Drugs. 42, 1, p. 127-135 9 p.

  Research output: Contribution to journal › Article › peer-review

  • navitoclax 100%
  • Sorafenib 72%
  • Hepatocellular Carcinoma 47%
  • Neoplasms 18%
  • Maximum Tolerated Dose 13%
• 2023

  Anal Carcinoma, Version 2.2023

  Benson, A. B., Venook, A. P., Al-Hawary, M. M., Azad, N., Chen, Y. J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., Grem, J. L., Randolph Hecht, J., Hoffe, S., Hubbard, J., Hunt, S., Hussan, H., Jeck, W., Johung, K. L., Joseph, N., Kirilcuk, N., & 23 othersKrishnamurthi, S., Maratt, J., Messersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stotsky-Himelfarb, E., Tavakkoli, A., Willett, C. G., Williams, G., Algieri, F., Gurski, L. & Katie Stehman, P. A. C., Jun 2023, In: JNCCN Journal of the National Comprehensive Cancer Network. 21, 6, p. 653-677 25 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Carcinoma 100%
  • Anus Neoplasms 29%
  • Surgical Oncology 29%
  • Radiation Oncology 26%
  • Medical Oncology 25%

• Association between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated with First-line Pembrolizumab

  Saberzadeh-Ardestani, B., Jones, J. C., Hubbard, J. M., McWilliams, R. R., Halfdanarson, T. R., Shi, Q., Sonbol, M. B., Ticku, J., Jin, Z. & Sinicrope, F. A., Feb 22 2023, In: JAMA Network Open. 6, 2, p. E230400

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pembrolizumab 100%
  • Colorectal Neoplasms 56%
  • Survival 39%
  • Neoplasm Metastasis 15%
  • DNA Repair-Deficiency Disorders 14%

• Association of Age with Treatment-Related Adverse Events and Survival in Patients with Metastatic Colorectal Cancer

  Meng, L., Thapa, R., Delgado, M. G., Gomez, M. F., Ji, R., Knepper, T. C., Hubbard, J. M., Wang, X., Permuth, J. B., Kim, R. D., Laber, D. A. & Xie, H., 2023, In: JAMA Network Open. 6, 6, p. E2320035

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Colorectal Neoplasms 100%
  • Survival 69%
  • Abdominal Pain 27%
  • Mutation 26%
  • Cohort Studies 21%

• Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer

  McGarrah, P., Hubbard, J., Novotny, P. J., Branda, M. E., Sargent, D. S., Morton, R. F., Fuchs, C. S., Benson, A. B., Williamson, S. K., Findlay, B. P., Alberts, S. R., Goldberg, R. M. & Sloan, J. A., Jan 1 2023, In: Cancer Control. 30

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Colorectal Neoplasms 100%
  • Quality of Life 81%
  • Survival 69%
  • Oxaliplatin 42%
  • Leucovorin 32%

• Comparing Oncologic Outcomes and Toxicity for Combined Modality Therapy vs. Carbon-Ion Radiotherapy for Previously Irradiated Locally Recurrent Rectal Cancer

  Jeans, E. B., Ebner, D. K., Takiyama, H., Qualls, K., Cunningham, D. A., Waddle, M. R., Jethwa, K. R., Harmsen, W. S., Hubbard, J. M., Dozois, E. J., Mathis, K. L., Tsuji, H., Merrell, K. W., Hallemeier, C. L., Mahajan, A., Yamada, S., Foote, R. L. & Haddock, M. G., Jun 2023, In: Cancers. 15, 11, 3057.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Heavy Ion Radiotherapy 100%
  • Combined Modality Therapy 79%
  • Rectal Neoplasms 65%
  • Costs and Cost Analysis 17%
  • Survival 15%

• Completion of Genetic Testing and Incidence of Pathogenic Germline Mutation among Patients with Early-Onset Colorectal Cancer: A Single Institution Analysis

  Storandt, M. H., Rogen, K. R., Iyyangar, A., Schnell, R. R., Mitchell, J. L., Hubbard, J. M., Sinicrope, F. A., Jatoi, A., Mahipal, A., Shi, Q. & Jin, Z., Jul 2023, In: Cancers. 15, 14, 3570.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Germ-Line Mutation 100%
  • Genetic Testing 91%
  • Colorectal Neoplasms 70%
  • Hereditary Nonpolyposis Colorectal Neoplasms 49%
  • Incidence 43%

• Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

  Ou, F. S., Ahn, D. H., Dixon, J. G., Grothey, A., Lou, Y., Kasi, P. M., Hubbard, J. M., Van Cutsem, E., Saltz, L. B., Schmoll, H. J., Goldberg, R. M., Venook, A. P., Hoff, P., Douillard, J. Y., Hecht, J. R., Hurwitz, H., Punt, C. J. A., Koopman, M., Bokemeyer, C., Fuchs, C. S., & 11 othersDiaz-Rubio, E., Tebbutt, N. C., Cremolini, C., Kabbinavar, F. F., Bekaii-Saab, T., Chibaudel, B., Yoshino, T., Zalcberg, J., Adams, R. A., de Gramont, A. & Shi, Q., Aug 2023, In: Cancers. 15, 16, 4117.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Colorectal Neoplasms 100%
  • Databases 75%
  • Survival 69%
  • Response Evaluation Criteria in Solid Tumors 58%
  • Proportional Hazards Models 10%

• Patient-reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501)

  Snyder, R. A., Dueck, A. C., Fruth, B., Shi, Q., Hubbard, J. M., Herman, J. M., O'Reilly, E. M. & Katz, M. H. G., Oct 1 2023, In: Annals of surgery. 278, 4, p. 598-608 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Neoadjuvant Therapy 100%
  • Terminology 87%
  • Pancreatic Neoplasms 82%
  • Patient Reported Outcome Measures 59%
  • Clinical Trials 56%

• Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies

  Zhu, M., Taylor, W. R., Mahoney, D. W., Then, S. S., Berger, C. K., Burger, K. N., Gonser, A. M., Doering, K. A., Xie, H., Foote, P. H., Kaiser, M. W., Allawi, H. T., Hubbard, J. M. & Kisiel, J. B., Dec 2023, In: Cancers. 15, 24, 5778.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Genetic Markers 83%
  • Plasma Cells 79%
  • Colorectal Neoplasms 63%
  • Recurrence 45%

• Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer

  Emiloju, O. E., Zhu, M., Xie, H., Jin, Z., Sinicrope, F. A. & Hubbard, J. M., Dec 2023, In: Current treatment options in oncology. 24, 12, p. 1739-1757 19 p.

  Research output: Contribution to journal › Review article › peer-review

  • Microsatellite Repeats 100%
  • Colorectal Neoplasms 75%
  • Vascular Endothelial Growth Factor A 49%
  • Anti-Idiotypic Antibodies 48%
  • Drug Therapy 44%

• Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study

  Borad, M. J., Bai, L. Y., Richards, D., Mody, K., Hubbard, J., Rha, S. Y., Soong, J., McCormick, D., Tse, E., O'Brien, D., Bayat, A., Ahn, D., Davis, S. L., Park, J. O. & Oh, D. Y., Mar 2023, In: Hepatology. 77, 3, p. 760-773 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Cholangiocarcinoma 100%
  • gemcitabine 96%
  • Cisplatin 78%
  • Confidence Intervals 51%
  • Progression-Free Survival 39%

• Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer

  Kelly, R. J., Bever, K., Chao, J., Ciombor, K. K., Eng, C., Fakih, M., Goyal, L., Hubbard, J., Iyer, R., Kemberling, H. T., Krishnamurthi, S., Ku, G., Mordecai, M. M., Morris, V. K., Paulson, A. S., Peterson, V., Shah, M. A. & Le, D. T., Jun 7 2023, In: Journal for ImmunoTherapy of Cancer. 11, 6, e006658.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Gastrointestinal Neoplasms 100%
  • Practice Guidelines 78%
  • Immunotherapy 73%
  • Neoplasms 27%
  • Programmed Cell Death 1 Receptor 20%

• Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

  MOUNTAINEER investigators, May 2023, In: The Lancet Oncology. 24, 5, p. 496-508 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Trastuzumab 100%
  • Colorectal Neoplasms 66%
  • Drug Therapy 49%
  • B 31 8%
  • Diarrhea 8%

• Understanding Suboptimal Response to Immune Checkpoint Inhibitors

  Zhu, M., Zhang, H., Pedersen, K. S., Foster, N. R., Jaszewski, B. L., Liu, X., Hirdler, J. B., An, Z., Bekaii-Saab, T. S., Halfdanarson, T. R., Boland, P. M., Yan, Y., Hubbard, J. H., Ma, W. W., Yoon, H. H., Revzin, A., Fernandez-Zapico, M. E., Overman, M. J., McWilliams, R. R. & Dong, H., Apr 2023, In: Advanced Biology. 7, 4, 2101319.

  Research output: Contribution to journal › Article › peer-review

  • Chemotherapy 100%
  • Cytolytic 97%
  • T-cells 49%
  • Cytotoxicity 49%
  • Patient monitoring 42%
• 2022

  A feasibility study of virtual group therapy to improve quality of life of cancer caregivers

  Lapid, M. I., Atherton, P. J., Kung, S., Clark, M. M., Sloan, J. A., Whitford, K. J., Hubbard, J. M., Gentry, M. T., Miller, J. J. & Rummans, T. A., 2022, In: Journal of Psychosocial Oncology. 40, 6, p. 854-867 14 p.

  Research output: Contribution to journal › Article › peer-review

  • group therapy 100%
  • Group Psychotherapy 89%
  • Feasibility Studies 89%
  • cancer 78%
  • caregiver 73%

• A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma

  Ahn, D. H., Uson Junior, P. L. S., Masci, P., Kosiorek, H., Halfdanarson, T. R., Mody, K., Babiker, H., DeLeon, T., Sonbol, M. B., Gores, G., Smoot, R., Bekaii-Saab, T., Mahipal, A., Mansfield, A., Tran, N. H., Hubbard, J. M. & Borad, M. J., Feb 2022, In: Investigational New Drugs. 40, 1, p. 134-141 8 p.

  Research output: Contribution to journal › Article › peer-review

  • ponatinib 100%
  • Fibroblast Growth Factor Receptors 77%
  • Biliary Tract Neoplasms 71%
  • Cholangiocarcinoma 69%
  • Progression-Free Survival 18%

• A prospective, randomized trial of patient-reported outcome measures to drive management decisions in hematology and oncology

  Warsame, R., Cook, J., Fruth, B., Hubbard, J., Croghan, K., Price, K. A. R., Jatoi, A., Kumar, S., Thompson, C., Buckner, J., Dispenzieri, A., Sloan, J. & Dueck, A. C., Oct 2022, In: Contemporary Clinical Trials Communications. 29, 100964.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Patient Reported Outcome Measures 100%
  • Hematology 97%
  • Drive 93%
  • Quality of Life 54%
  • Amyloidosis 14%

• Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report

  Johnson, S., Parsons, M., Dorff, T., Moran, M. S., Ward, J. H., Cohen, S. A., Akerley, W., Bauman, J., Hubbard, J., Spratt, D. E., Bylund, C. L., Swire-Thompson, B., Onega, T., Scherer, L. D., Tward, J. & Fagerlin, A., Jul 1 2022, In: Journal of the National Cancer Institute. 114, 7, p. 1036-1039 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Social Media 100%
  • Communication 60%
  • Nonparametric Statistics 38%
  • Neoplasms 26%
  • Data Accuracy 21%

• Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers

  Hogenson, T. L., Xie, H., Phillips, W. J., Toruner, M. D., Li, J. J., Horn, I. P., Kennedy, D. J., Almada, L. L., Marks, D. L., Carr, R. M., Toruner, M., Sigafoos, A. N., Koenig-Kappes, A. N., Olson, R. L. O., Tolosa, E. J., Zhang, C., Li, H., Doles, J. D., Bleeker, J., Barrett, M. T., & 19 othersBoyum, J. H., Kipp, B. R., Mahipal, A., Hubbard, J. M., Scheffler Hanson, T. J., Petersen, G. M., Dasari, S., Oberg, A. L., Truty, M. J., Graham, R. P., Levy, M. J., Zhu, M., Billadeau, D. D., Adjei, A. A., Dusetti, N., Iovanna, J. L., Bekaii-Saab, T. S., Ma, W. W. & Fernandez-Zapico, M. E., Nov 22 2022, In: JCI Insight. 7, 22, e158060.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Organoids 100%
  • Gastrointestinal Neoplasms 90%
  • Culture Media 69%
  • Aptitude 51%
  • Tissue Donors 22%

• Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

  Schoenfeld, J. D., Giobbie-Hurder, A., Ranasinghe, S., Kao, K. Z., Lako, A., Tsuji, J., Liu, Y., Brennick, R. C., Gentzler, R. D., Lee, C., Hubbard, J., Arnold, S. M., Abbruzzese, J. L., Jabbour, S. K., Uboha, N. V., Stephans, K. L., Johnson, J. M., Park, H., Villaruz, L. C., Sharon, E., & 17 othersStreicher, H., Ahmed, M. M., Lyon, H., Cibuskis, C., Lennon, N., Jhaveri, A., Yang, L., Altreuter, J., Gunasti, L., Weirather, J. L., Mak, R. H., Awad, M. M., Rodig, S. J., Chen, H. X., Wu, C. J., Monjazeb, A. M. & Hodi, F. S., Feb 2022, In: The Lancet Oncology. 23, 2, p. 279-291 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • tremelimumab 100%
  • durvalumab 96%
  • Non-Small Cell Lung Carcinoma 49%
  • Radiotherapy 38%
  • Hyponatremia 10%

• Pancreatic cancer risk to siblings of probands in bilineal cancer settings

  Rabe, K. G., Stevens, M. A., Hernández, A. T., Chandra, S., Hubbard, J. M., Kemppainen, J. L., Majumder, S. & Petersen, G. M., May 2022, In: Genetics in Medicine. 24, 5, p. 1008-1016 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Pancreatic Neoplasms 100%
  • Neoplasms 34%
  • Incidence 15%
  • Neoplasm Genes 8%
  • Registries 6%

• Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

  Hubbard, J. M., Yin, J., Schenk, E. L., Qin, R., Reid, J. M., Strand, C., Fiskum, J., Menefee, M., Lin, G., Doyle, L. A., Ivy, P., Erlichman, C., Adjei, A., Haluska, P. & Costello, B. A., Feb 2022, In: Investigational New Drugs. 40, 1, p. 115-123 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cediranib 100%
  • AZD 6244 96%
  • Mitogen-Activated Protein Kinase Kinases 63%
  • Neoplasms 18%
  • Vascular Endothelial Growth Factor A 16%

• Rectal Cancer, Version 2.2022

  Benson, A. B., Venook, A. P., Al-Hawary, M. M., Azad, N., Chen, Y. J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hecht, J. R., Hoffe, S., Hubbard, J., Hunt, S., Jeck, W., Johung, K. L., Kirilcuk, N., Krishnamurthi, S., & 20 othersMaratt, J. K., Messersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stotsky-Himelfarb, E., Tavakkoli, A., Willett, C. G., Gregory, K. & Gurski, L., Oct 2022, In: JNCCN Journal of the National Comprehensive Cancer Network. 20, 10, p. 1139-1167 29 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Rectal Neoplasms 100%
  • Neoadjuvant Therapy 75%
  • Guidelines 62%
  • Survivorship 39%
  • Polyps 33%

• Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study

  Hubbard, J. M., Toke, E. R., Moretto, R., Graham, R. P., Youssoufian, H., Lorincz, O., Molnár, L., Csiszovszki, Z., Mitchell, J. L., Wessling, J., Tóth, J. & Cremolini, C., Jul 1 2022, In: Clinical Cancer Research. 28, 13, p. 2818-2829 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Colorectal Neoplasms 100%
  • Safety 73%
  • Microsatellite Repeats 48%
  • Therapeutics 20%
  • Maintenance Chemotherapy 16%
• 2021

  Cases in the management of metastatic colorectal cancer: Rechallenge with chemotherapy after regorafenib in a patient with RAS/BRAF wild-type disease

  Hubbard, J. M., Apr 2021, In: Clinical Advances in Hematology and Oncology. 19, 4, p. 1-7 7 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Colon cancer, Version 2.2021

  Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y. J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hecht, J. R., Hoffe, S., Hubbard, J., Hunt, S., Johung, K. L., Kirilcuk, N., Krishnamurthi, S., & 19 othersMessersmith, W. A., Meyerhardt, J., Miller, E. D., Mulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Gregory, K. M. & Gurski, L. A., 2021, In: JNCCN Journal of the National Comprehensive Cancer Network. 19, 3, p. 329-359 31 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Colonic Neoplasms 100%
  • Colorectal Neoplasms 52%
  • Biosimilar Pharmaceuticals 30%
  • Guidelines 28%
  • Microsatellite Instability 27%
  8 Scopus citations

• Considerations in the management of younger patients With colorectal cancer: Q&A

  Hubbard, J. M., Eng, C., Cremolini, C. & Marshall, J. L., Jun 1 2021, In: Clinical advances in hematology & oncology : H&O. 19, 6, p. 15-17 3 p.

  Research output: Contribution to journal › Article › peer-review

• FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience

  Gile, J. J., Ou, F-S., Mahipal, A., Larson, J. J., Mody, K., Jin, Z., Hubbard, J., Halfdanarson, T., Alberts, S. R., Jatoi, A., Mc Williams, R. R., Ma, W. W., Ilyas, S., Smoot, R., Roberts, L. R., Gores, G., Borad, M., Bekaii-Saab, T. S. & Tran, N. H., 2021, In: JCO Precision Oncology. 5, p. 1228-1240 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Fibroblast Growth Factor Receptors 100%
  • Cholangiocarcinoma 89%
  • Progression-Free Survival 28%
  • Hyperphosphatemia 20%
  • Second Primary Neoplasms 17%

• Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience

  Jethwa, K. R., Day, C. N., Sandhyavenu, H., Gonuguntla, K., Harmsen, W. S., Breen, W. G., Routman, D. M., Garda, A. E., Hubbard, J. M., Halfdanarson, T. R., Neben-Wittich, M. A., Merrell, K. W., Hallemeier, C. L. & Haddock, M. G., May 2021, In: Clinical and Translational Radiation Oncology. 28, p. 17-23 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Intensity-Modulated Radiotherapy 100%
  • Anal Canal 91%
  • Squamous Cell Carcinoma 68%
  • Confidence Intervals 42%
  • Recurrence 29%
  1 Scopus citations

• Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines

  Bonney, G. K., Chew, C. A., Lodge, P., Hubbard, J., Halazun, K. J., Trunecka, P., Muiesan, P., Mirza, D. F., Isaac, J., Laing, R. W., Iyer, S. G., Chee, C. E., Yong, W. P., Muthiah, M. D., Panaro, F., Sanabria, J., Grothey, A., Moodley, K., Chau, I., Chan, A. C. Y., & 7 othersWang, C. C., Menon, K., Sapisochin, G., Hagness, M., Dueland, S., Line, P. D. & Adam, R., Nov 2021, In: The Lancet Gastroenterology and Hepatology. 6, 11, p. 933-946 14 p.

  Research output: Contribution to journal › Review article › peer-review

  • Liver Transplantation 100%
  • Guidelines 70%
  • Neoplasm Metastasis 67%
  • Liver 56%
  • Transplants 49%

• Management of non-colorectal digestive cancers with microsatellite instability

  Zhu, M., Jin, Z. & Hubbard, J. M., Feb 2 2021, In: Cancers. 13, 4, p. 1-21 21 p., 651.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Microsatellite Instability 100%
  • Digestive System Neoplasms 32%
  • Neoplasms 26%
  • Gastrointestinal Neoplasms 24%
  • Tumor Microenvironment 21%
  1 Scopus citations

• Novel methylated DNA markers in the surveillance of colorectal cancer recurrence

  Xie, H., Mahoney, D. W., Foote, P. H., Burger, K. N., Doering, K. A., Taylor, W. R., Then, S. S., Cao, X., McGlinch, M., Berger, C. K., Wu, T. T., Hubbard, J. M., Allawi, H. T., Kaiser, M. W., Lidgard, G. P., Ahlquist, D. A. & Kisiel, J. B., Jan 1 2021, In: Clinical Cancer Research. 27, 1, p. 141-149 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Genetic Markers 100%
  • Colorectal Neoplasms 75%
  • Recurrence 54%
  • Area Under Curve 25%
  • Forests 9%
  2 Scopus citations

• Older adult oncology, version 1.2021: Featured updates to the NCCN guidelines

  Dotan, E., Walter, L. C., Browner, I. S., Clifton, K., Cohen, H. J., Extermann, M., Gross, C., Gupta, S., Hollis, G., Hubbard, J., Jagsi, R., Keating, N. L., Kessler, E., Koll, T., Korc-Grodzicki, B., McKoy, J. M., Misra, S., Moon, D., O’Connor, T., Owusu, C., & 12 othersRosko, A., Russell, M., Sedrak, M., Siddiqui, F., Stella, A., Stirewalt, D. L., Subbiah, I. M., Tew, W. P., Williams, G. R., Hollinger, L., George, G. V. & Sundar, H., Sep 2021, In: JNCCN Journal of the National Comprehensive Cancer Network. 19, 9, p. 1006-1019 14 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Guidelines 65%
  • Neoplasms 24%
  • Risk Assessment 21%
  • Therapeutics 16%
  • Health 12%

• Outcomes of COVID-19 in patients with cancer: A closer look at pre-emptive routine screening strategies

  Xie, Z., Saliba, A. N., Abeykoon, J., Majeed, U., Almquist, D. R., Wiedmeier-Nutor, J. E., Bezerra, E., Andrade-Gonzalez, X., Hickman, A., Sorenson, K., Rakshit, S., Wee, C., Tella, S. H., Kommalapati, A., Abdallah, N., Pritchett, J., de Andrade, M., Uprety, D., Badley, A., Manochakian, R., & 9 othersAilawadhi, S., Bryce, A. H., Hubbard, J. M., Gangat, N., Thompson, C. A., Witzig, T. E., McWilliams, R. R., Leventakos, K. & Halfdanarson, T. R., Sep 1 2021, In: JCO Oncology Practice. 17, 9, p. E1382-E1393

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cancer 100%
  • hospital admission 67%
  • mortality 39%
  • Neoplasms 35%
  • asymptomatic patients 31%

• Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance)

  Tran, N. H., Foster, N. R., Mahipal, A., Byrne, T., Hubbard, J., Silva, A., Mody, K., Alberts, S. & Borad, M. J., Aug 2021, In: Investigational New Drugs. 39, 4, p. 1072-1080 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • TH 302 100%
  • Sorafenib 63%
  • Renal Cell Carcinoma 49%
  • Hepatocellular Carcinoma 13%
  • Maximum Tolerated Dose 10%

• Research on anal squamous cell carcinoma: Systemic therapy strategies for anal cancer

  Carr, R. M., Jin, Z. & Hubbard, J., May 1 2021, In: Cancers. 13, 9, 2180.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Anus Neoplasms 100%
  • Squamous Cell Carcinoma 60%
  • Standard of Care 20%
  • Social Stigma 14%
  • Papillomavirus Vaccines 13%

• The diagnosis and outcome of Krukenberg tumors

  Xie, H., Erickson, B. J., Sheedy, S. P., Yin, J. & Hubbard, J. M., Apr 2021, In: Journal of Gastrointestinal Oncology. 12, 2, p. 226-236 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Krukenberg Tumor 100%
  • Ovarian Neoplasms 45%
  • Computer Neural Networks 25%
  • Area Under Curve 24%
  • Confidence Intervals 23%

• The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study: TILs for ADJ-untreated stage II colon cancer

  Francini, E., Ou, F. S., Lazzi, S., Petrioli, R., Multari, A. G., Pesola, G., Messuti, L., Colombo, E., Livellara, V., Bazzurri, S., Cherri, S., Miano, S. T., Wolfe, E. G., Alberts, S. R., Hubbard, J. M., Yoon, H. H. & Francini, G., Feb 2021, In: Translational Oncology. 14, 2, 100973.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tumor-Infiltrating Lymphocytes 100%
  • Adjuvant Chemotherapy 79%
  • Colonic Neoplasms 71%
  • Cohort Studies 53%
  • Survival 11%

• Treatment Selection for Younger Patients With Metastatic Colorectal Cancer

  Hubbard, J. M., Jun 2021, In: Clinical Advances in Hematology and Oncology. 19, 6, p. 11-15 5 p.

  Research output: Contribution to journal › Article › peer-review
• 2020

  Arti Hurria, M.D. A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology

  On behalf of the Alliance Cancer in the Older Adult Committee, Mar 2020, In: Journal of Geriatric Oncology. 11, 2, p. 179-183 5 p.

  Research output: Contribution to journal › Short survey › peer-review

  Open Access
  1 Scopus citations

• Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer

  Jethwa, K. R., Jang, S., Mullikin, T. C., Harmsen, W. S., Petersen, M. M., Olivier, K. R., Park, S. S., Neben-Wittich, M. A., Hubbard, J. M., Sandhyavenu, H., Whitaker, T. J., Waltman, L. A., Kipp, B. R., Merrell, K. W., Haddock, M. G. & Hallemeier, C. L., May 2020, In: Radiotherapy and Oncology. 146, p. 29-36 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Radiosurgery 100%
  • Colorectal Neoplasms 72%
  • Neoplasm Metastasis 56%
  • Mutation 36%
  • Survival 35%
  3 Scopus citations

• Biomarkers of aging (with a clinical potential in oncology)

  Hubbard, J. M., Jan 1 2020, Geriatric Oncology. Springer International Publishing, p. 395-405 11 p.

  Research output: Chapter in Book/Report/Conference proceeding › Chapter

  • Frailty 100%
  • Biomarkers 85%
  • Neoplasms 28%
  • Second Primary Neoplasms 24%
  • Telomere 24%

• Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)

  Xie, H., Lafky, J. M., Morlan, B. W., Stella, P. J., Dakhil, S. R., Gross, G. G., Loui, W. S., Hubbard, J. M., Alberts, S. R. & Grothey, A., 2020, In: Therapeutic Advances in Medical Oncology. 12

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Sorafenib 100%
  • Salvage Therapy 96%
  • Bevacizumab 90%
  • Vascular Endothelial Growth Factor A 70%
  • Colorectal Neoplasms 64%
  3 Scopus citations

• Rectal cancer, version 6.2020: Featured updates to the NCCN guidelines

  Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y. J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Garrido-Laguna, I., Grem, J. L., Gunn, A., Hoffe, S., Hubbard, J., Hunt, S., Kirilcuk, N., Krishnamurthi, S., Messersmith, W. A., Meyerhardt, J., Miller, E. D., & 16 othersMulcahy, M. F., Nurkin, S., Overman, M. J., Parikh, A., Patel, H., Pedersen, K., Saltz, L., Schneider, C., Shibata, D., Skibber, J. M., Sofocleous, C. T., Stoffel, E. M., Stotsky-Himelfarb, E., Willett, C. G., Johnson-Chilla, A. & Gurski, L. A., Jul 2020, In: JNCCN Journal of the National Comprehensive Cancer Network. 18, 7, p. 807-815 9 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Rectal Neoplasms 100%
  • Guidelines 62%
  • Neoadjuvant Therapy 37%
  • Sigmoid Colon 35%
  • Rectum 32%
  26 Scopus citations

• Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma

  Xie, H., Liu, J., Yin, J., Ogden, J. R., Mahipal, A., McWilliams, R. R., Truty, M. J., Bekaii-Saab, T. S., Petersen, G. M., Jatoi, A., Hubbard, J. M. & Ma, W. W., Nov 1 2020, In: Oncologist. 25, 11, p. e1681-e1690

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Adenocarcinoma 100%
  • Neoadjuvant Therapy 73%
  • Confidence Intervals 38%
  • Survival 35%
  • Therapeutics 20%
  1 Scopus citations

• Survival benefit of combination chemotherapy in elderly patients with metastatic pancreatic ductal adenocarcinoma

  Xie, H., Liu, J., Ogden, J. R., Yin, J., Jatoi, A., Hubbard, J. M., McWilliams, R. R., Mahipal, A., Petersen, G. M., Bekaii-Saab, T. S. & Ma, W. W., Aug 1 2020, In: American Journal of Clinical Oncology: Cancer Clinical Trials. 43, 8, p. 586-590 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Combination Drug Therapy 100%
  • Adenocarcinoma 77%
  • Elderly 66%
  • Survival 54%
  • Age Groups 44%

• The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials

  Sonbol, M. B., Mountjoy, L. J., Firwana, B., Liu, A. J., Almader-Douglas, D., Mody, K., Hubbard, J., Borad, M., Ahn, D. H., Murad, M. H. & Bekaii-Saab, T., Mar 2020, In: JAMA Oncology. 6, 3

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Network Meta-Analysis 100%
  • Bevacizumab 83%
  • Colorectal Neoplasms 59%
  • Systematic Reviews 54%
  • Maintenance 52%
  14 Scopus citations
• 2019

  Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma

  Kommalapati, A., Tella, S. H., Goyal, G., Borad, M., Alberts, S. R., Roberts, L., Hubbard, J. M., Durgin, L., Cleary, S. & Mahipal, A., Mar 2019, In: HPB. 21, 3, p. 379-386 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cholangiocarcinoma 100%
  • Survival 48%
  • Liver 22%
  • Therapeutics 14%
  • Insurance 8%
  2 Scopus citations